 This will be a randomized, double blind, placebo controlled, parallel group study in approximately 90 subjects with moderate-severe AD Eczema Area and Severity Index EASI 12 and 48 0-72 scale. Following a run-in subjects will be randomized to receive either oral 30 mg ZPL-3893787 once daily od or placebo od for 8 weeks 56 days. 